Affordable Access

deepdyve-link
Publisher Website

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors
  • Black, Mark D
  • Stevens, Rachel J
  • Rogacki, Nancy
  • Featherstone, Robert E
  • Senyah, Yaw
  • Giardino, Odessa
  • Borowsky, Beth
  • Stemmelin, Jeanne
  • Cohen, Caroline
  • Pichat, Philippe
  • Arad, Michal
  • Barak, Segev
  • De Levie, Amaya
  • Weiner, Ina
  • Griebel, Guy
  • Varty, Geoffrey B
Type
Published Article
Journal
Psychopharmacology
Publication Date
May 01, 2011
Volume
215
Issue
1
Pages
149–163
Identifiers
DOI: 10.1007/s00213-010-2124-0
PMID: 21181124
Source
Medline
License
Unknown

Abstract

These preclinical data suggest that AVE1625 may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. In addition, an improved side-effect profile was seen, with potential to ameliorate the EPS and weight gain issues with currently available treatments.

Report this publication

Statistics

Seen <100 times